- Home
- HBT vs NUVB Comparison
HBT vs NUVB Comparison
Compare HBT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- NUVB
- Stock Information
- Founded
- HBT 1920
- NUVB 2018
- Country
- HBT United States
- NUVB United States
- Employees
- HBT N/A
- NUVB N/A
- Industry
- HBT Major Banks
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- NUVB Health Care
- Exchange
- HBT Nasdaq
- NUVB Nasdaq
- Market Cap
- HBT 706.0M
- NUVB 679.9M
- IPO Year
- HBT 2019
- NUVB N/A
- Fundamental
- Price
- HBT $24.07
- NUVB $2.20
- Analyst Decision
- HBT Hold
- NUVB Strong Buy
- Analyst Count
- HBT 5
- NUVB 5
- Target Price
- HBT $25.25
- NUVB $8.20
- AVG Volume (30 Days)
- HBT 26.6K
- NUVB 4.2M
- Earning Date
- HBT 07-21-2025
- NUVB 05-07-2025
- Dividend Yield
- HBT 3.57%
- NUVB N/A
- EPS Growth
- HBT 6.07
- NUVB N/A
- EPS
- HBT 2.38
- NUVB N/A
- Revenue
- HBT $227,041,000.00
- NUVB $10,957,000.00
- Revenue This Year
- HBT $8.82
- NUVB $95.27
- Revenue Next Year
- HBT $2.74
- NUVB $345.44
- P/E Ratio
- HBT $9.83
- NUVB N/A
- Revenue Growth
- HBT 1.69
- NUVB N/A
- 52 Week Low
- HBT $18.16
- NUVB $1.54
- 52 Week High
- HBT $26.25
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- HBT 50.20
- NUVB 54.88
- Support Level
- HBT $23.12
- NUVB $2.11
- Resistance Level
- HBT $24.44
- NUVB $2.42
- Average True Range (ATR)
- HBT 0.61
- NUVB 0.16
- MACD
- HBT -0.10
- NUVB -0.01
- Stochastic Oscillator
- HBT 35.67
- NUVB 67.47
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).